Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mevacor reverses atherosclerosis in patients without CHD history -- Merck ACAPS study.

Executive Summary

MERCK MEVACOR LABELING INCLUDES STUDY OF USE IN PATIENTS WITH NO CHD, Merck announced April 3. The Asymptomatic Carotid Artery Progression Study showing that Mevacor reverses atherosclerosis in patients with no history of coronary heart disease was approved for inclusion in labeling by FDA on Feb. 9. Merck announced the labeling change following public release of the Bristol-Myers Squibb CARE study, which concluded that Pravachol reduces heart disease in post-MI patients with average cholesterol levels ("The Pink Sheet" April 1, T&G-10).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027969

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel